News
Curated oncology headlines from reputable sources, ranked by importance with Claude Opus 5.
News about: Larynx → cancer profile · × Clear filters
TG4050 neoantigen vaccine as adjuvant treatment in head and neck cancer: no relapses among 16 vaccinated patients in a randomised phase 1 trial
In a randomised phase 1 trial (NCT04183166), patients with completely resected head and neck squamous cell carcinoma received TG4050, an individually designed vaccine on a Modified Vaccinia Ankara viral vector encoding up to 30 predicted patient-specific neoantigens. In the arm vaccinated immediately after adjuvant therapy, none of the 16 evaluable patients relapsed at a median follow-up of 30 mon…
Long-Term Follow-Up of JCOG1008, a Randomized Phase II/III Trial of Chemoradiotherapy Comparing 3-Weekly Cisplatin With Weekly Cisplatin in Postoperative Head and Neck Cancer
Five-year follow-up of the phase 2/3 JCOG1008 trial (n=261) confirmed that weekly cisplatin (40 mg/m2, seven cycles) is noninferior to the 3-weekly schedule (100 mg/m2, three cycles) in postoperative chemoradiotherapy for high-risk locally advanced squamous cell carcinoma of the head and neck. At a median follow-up of 5.6 years, 5-year overall survival was 71.2% in the weekly arm versus 58.7% in t…
Amivantamab in Recurrent/Metastatic Head and Neck Squamous Cell Cancer After Checkpoint Inhibitor and Chemotherapy: Pivotal Results From the Phase Ib/II OrigAMI-4 Study
The phase Ib/II OrigAMI-4 study reports pivotal results for amivantamab, a bispecific EGFR-MET antibody, in patients with recurrent or metastatic head and neck squamous cell carcinoma who progressed after checkpoint inhibitor therapy and chemotherapy. This represents a heavily pretreated population with limited therapeutic options, and the study was published in the Journal of Clinical Oncology (V…
Pembrolizumab With or Without Lenvatinib as First-Line Therapy for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: Phase III LEAP-010 Study
The Phase III LEAP-010 trial, published in the Journal of Clinical Oncology, evaluated whether adding the multi-kinase inhibitor lenvatinib to pembrolizumab improves outcomes in patients with PD-L1-positive recurrent or metastatic head and neck squamous cell carcinoma treated in the first-line setting. The study compared pembrolizumab plus lenvatinib against pembrolizumab plus placebo, with overal…